|
Market Closed -
Hong Kong S.E.
12:08:03 04/09/2026 +04
|
5-day change | 1st Jan Change | ||
| 3.080 HKD | 0.00% |
|
+0.33% | +4.41% |
| 08-31 | HighTide Therapeutics, Inc. Reports Earnings Results for the Half Year Ended June 30, 2026 | CI |
| 07-02 | HighTide Therapeutics, CEO Terminate Loan Contract on Bourse's Concerns | MT |
Company Valuation: HighTide Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2023 | 2024 | 2025 |
|---|---|---|---|
| Market Cap 1 | 6,056 | 614.3 | 1,515 |
| Change | - | -89.86% | 146.54% |
| Enterprise Value (EV) 1 | 5,336 | 201.5 | 1,139 |
| Change | - | -96.22% | 464.94% |
| P/E | -3.25x | -1.41x | -5.19x |
| PBR | 8.62x | 1.45x | 4.93x |
| PEG | 0.2x | 0x | 0.1x |
| Capitalization / Revenue | - | - | - |
| EV / Revenue | - | - | - |
| EV / EBITDA | -11.9x | -0.45x | -5.13x |
| EV / EBIT | -11.9x | -0.45x | -5.09x |
| EV / FCF | - | - | - |
| FCF Yield | - | - | - |
| Dividend per Share 2 | - | - | - |
| Rate of return | - | - | - |
| EPS 2 | -3.617 | -0.8445 | -0.5106 |
| Distribution rate | - | - | - |
| Net sales | - | - | - |
| EBITDA 1 | -447.7 | -443.7 | -222.2 |
| EBIT 1 | -448.2 | -444.8 | -223.6 |
| Net income 1 | -939.3 | -381.8 | -245 |
| Net Debt 1 | -719.9 | -412.8 | -376 |
| Reference price 2 | 11.764 | 1.193 | 2.651 |
| Nbr of stocks (in thousands) | 514,771 | 514,771 | 571,326 |
| Announcement Date | 26/04/24 | 23/04/25 | 29/04/26 |
1CNY in Million2CNY
Estimates
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 224M | |
| 20.25x | 7.04x | 14.2x | 1.45% | 67.98B | |
| 36.9x | 9.64x | 29.44x | 0.04% | 64.94B | |
| -77.3x | 14.92x | -71.95x | -.--% | 27.58B | |
| -15.85x | 6.12x | -7.7x | -.--% | 26.06B | |
| 29.69x | 6.35x | 16.48x | -.--% | 25.74B | |
| 27.41x | 5.13x | 17.06x | -.--% | 20.09B | |
| 49.41x | 18.23x | 36.98x | 0.31% | 17.16B | |
| 1289.22x | 37.23x | 812.54x | -.--% | 14.92B | |
| 18.23x | 5.44x | 12.69x | -.--% | 14.62B | |
| Average | 153.11x | 12.23x | 95.53x | 0.2% | 27.93B | |
| Weighted average by Cap. | 82.01x | 10.35x | 51.60x | 0.38% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- 2511 Stock
- Valuation HighTide Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
